Magromag (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive metabolites that damage bacterial DNA, ribosomal proteins, and key metabolic enzymes like pyruvate‑ferredoxin oxidoreductase. This disruption interferes with carbohydrate metabolism and cell‑wall synthesis, leading to bacterial cell death.

The specific dose of Magromag is determined by the prescribing clinician based on the patient’s condition, renal function, and local guidelines. Healthcare professionals select the appropriate strength and dosing schedule for each individual case.

The safety of nitrofurantoin during pregnancy is not fully established, and it is classified as a pregnancy category with unknown risk. It should be used only if the potential benefit justifies the potential risk to the fetus. Caution is also advised during breastfeeding, and a healthcare provider should evaluate the situation.

To order Magromag, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any required import documentation.

The most common alternative for uncomplicated urinary tract infections is trimethoprim‑sulfamethoxazole. Nitrofurantoin (Magromag) is often preferred when resistance to trimethoprim‑sulfamethoxazole is high, as it has a different mechanism of action and retains activity against many resistant strains. However, nitrofurantoin is limited to lower urinary tract infections and requires adequate renal function for efficacy.

Magromag should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Magromag is taken orally with a full glass of water. It is usually recommended to take the medication with food or milk to reduce gastrointestinal irritation, unless the prescribing clinician advises otherwise.

Serious adverse reactions include pulmonary toxicity (interstitial pneumonitis or fibrosis), hepatic injury (hepatitis or elevated liver enzymes), and hemolytic anemia, especially in patients with glucose‑6‑phosphate dehydrogenase deficiency. Any signs of shortness of breath, jaundice, or sudden anemia should prompt immediate medical evaluation.

Magromag should be avoided in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to nitrofurantoin, or documented G6PD deficiency due to the risk of hemolysis. Caution is also advised for patients with a history of lung disease or liver dysfunction.